SCHEMBL4568360

SCHEMBL4568360

COc1ccc(CC(=O)c2cc(F)cc(Cl)c2)c(NC(=O)OC(C)(C)C)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
TAS1R2 Q8TE23 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
P2RX7 Q99572 2/20 0.36
EPHX2 P34913 1/20 0.36
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
HTT P42858 2/20 0.35
EPAS1 Q99814 1/20 0.35
PTGS2 P35354 1/20 0.35
ANO1 Q5XXA6 1/20 0.35
TP53 P04637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4568054 0.86 SMN1; SMN2 (0.47) MAPTMEN1KMT2AEPHX2NPC1
SCHEMBL4568062 0.86 MEN1 (0.45) MAPTMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL4568068 0.86 TAS1R3 (0.50) MAPTMEN1KMT2ATAS1R3TAS1R1
SCHEMBL4568049 0.86 RAB9A (0.46) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL4568061 0.86 NPC1 (0.46) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL4568362 0.85 CYP17A1 (0.37) MAPTMEN1KMT2AEPHX2NPC1
SCHEMBL4568358 0.85 GAA (0.42) MAPTMEN1KMT2ATAS1R3TAS1R1
SCHEMBL4568366 0.84 DYRK1A (0.37) MAPTMEN1KMT2AP2RX7EPHX2
SCHEMBL4568359 0.83 RAB9A (0.39) MAPTTAS1R3TAS1R1TAS1R2EPHX2
SCHEMBL4568361 0.83 TAS1R3 (0.41) MAPTMEN1KMT2ATAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R MAPT 3199/4885MEN1 2993/4885KMT2A 2056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.